In 2017, branded biologic sales in oncology, immunology, endocrinology, and nephrology across the major markets exceeded $80 billion. Sales from biosimilars in the
same therapy areas and regions totaled approximately $2.5 billion. Throughout our 2017-2027 forecast period, increasing numbers of branded biologics are set to lose 
patent protection, with biosimilars expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and
their biosimilars by therapeutic area, molecule, and region.